tetano
Editor, Senior Moderator
EBioMedicine
. 2021 Nov 7;73:103675.
doi: 10.1016/j.ebiom.2021.103675. Online ahead of print.
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
Kyle L O'Donnell[SUP] 1 [/SUP], Amanda N Pinski[SUP] 2 [/SUP], Chad S Clancy[SUP] 3 [/SUP], Tylisha Gourdine[SUP] 1 [/SUP], Kyle Shifflett[SUP] 1 [/SUP], Paige Fletcher[SUP] 1 [/SUP], Ilhem Messaoudi[SUP] 2 [/SUP], Andrea Marzi[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Following the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its rapid spread throughout the world, new viral variants of concern (VOC) have emerged. There is a critical need to understand the impact of the emerging variants on host response and disease dynamics to facilitate the development of vaccines and therapeutics.
Methods: Syrian golden hamsters are the leading small animal model that recapitulates key aspects of severe coronavirus disease 2019 (COVID-19). We performed intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (B.1.1.7, alpha) and South Africa (B.1.351, beta) and analyzed viral loads and host responses.
Findings: Similar gross and histopathologic pulmonary lesions were observed after infection with all three variants. Although differences in viral genomic copy numbers were noted in the lungs and oral swabs of challenged animals, infectious titers in the lungs were comparable between the variants. Antibody neutralization capacities varied, dependent on the original challenge virus and cross-variant protective capacity. Transcriptional profiling of lung samples 4 days post-challenge (DPC) indicated significant induction of antiviral pathways in response to all three challenges with a more robust inflammatory signature in response to B.1.1.7 infection. Furthermore, no additional mutations in the spike protein were detected at 4 DPC.
Interpretations: Although disease severity and viral shedding were not significantly different, the emerging VOC induced distinct humoral responses and transcriptional profiles compared to the ancestral virus. These observations suggest potential differences in acute early responses or alterations in immune modulation by VOC.
Funding: Intramural Research Program, NIAID, NIH; National Center for Research Resources, NIH; National Center for Advancing Translational Sciences, NIH.
Keywords: Animal model; COVID-19; Interstitial pneumonia; Pathogenesis; Severe acute respiratory syndrome coronavirus-2; Variants of concern.
. 2021 Nov 7;73:103675.
doi: 10.1016/j.ebiom.2021.103675. Online ahead of print.
Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model
Kyle L O'Donnell[SUP] 1 [/SUP], Amanda N Pinski[SUP] 2 [/SUP], Chad S Clancy[SUP] 3 [/SUP], Tylisha Gourdine[SUP] 1 [/SUP], Kyle Shifflett[SUP] 1 [/SUP], Paige Fletcher[SUP] 1 [/SUP], Ilhem Messaoudi[SUP] 2 [/SUP], Andrea Marzi[SUP] 4 [/SUP]
Affiliations
- PMID: 34758415
- DOI: 10.1016/j.ebiom.2021.103675
Abstract
Background: Following the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its rapid spread throughout the world, new viral variants of concern (VOC) have emerged. There is a critical need to understand the impact of the emerging variants on host response and disease dynamics to facilitate the development of vaccines and therapeutics.
Methods: Syrian golden hamsters are the leading small animal model that recapitulates key aspects of severe coronavirus disease 2019 (COVID-19). We performed intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1-2020) or VOC first identified in the United Kingdom (B.1.1.7, alpha) and South Africa (B.1.351, beta) and analyzed viral loads and host responses.
Findings: Similar gross and histopathologic pulmonary lesions were observed after infection with all three variants. Although differences in viral genomic copy numbers were noted in the lungs and oral swabs of challenged animals, infectious titers in the lungs were comparable between the variants. Antibody neutralization capacities varied, dependent on the original challenge virus and cross-variant protective capacity. Transcriptional profiling of lung samples 4 days post-challenge (DPC) indicated significant induction of antiviral pathways in response to all three challenges with a more robust inflammatory signature in response to B.1.1.7 infection. Furthermore, no additional mutations in the spike protein were detected at 4 DPC.
Interpretations: Although disease severity and viral shedding were not significantly different, the emerging VOC induced distinct humoral responses and transcriptional profiles compared to the ancestral virus. These observations suggest potential differences in acute early responses or alterations in immune modulation by VOC.
Funding: Intramural Research Program, NIAID, NIH; National Center for Research Resources, NIH; National Center for Advancing Translational Sciences, NIH.
Keywords: Animal model; COVID-19; Interstitial pneumonia; Pathogenesis; Severe acute respiratory syndrome coronavirus-2; Variants of concern.